As an immunomodulator, visfatin induces dose-dependent up-regulation of the pro- and anti-inflammatory cytokines, IL-1β, IL-6, IL-10, and TNF-α in human monocytes: visfatin is associated with sepsis, acute lung disease, atherosclerosis, and cancer [13,15]. This evidence concerns the gene IL1B and cancer.